D&D Pharmatech Reports P-II Trial Results on Zabopegdutide for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
D&D Pharmatech disclosed topline Phase II data for its GLP‑1‑like agent zabopegdutide in 67 overweight or obese patients with metabolic dysfunction‑associated steatohepatitis (MASH). After a 2‑week titration to a 40 mg weekly maintenance dose, 48‑week histology showed a 50% fibrosis‑stage improvement versus 15.8% on placebo, and a 62.5% rate of MASH resolution without fibrosis worsening. The trial also demonstrated combined fibrosis improvement and MASH resolution in 37.5% of participants. Results were presented at the EASL 2026 meeting.
This Medication Was Linked To A 56% Lower Risk Of Breast Cancer Recurrence
A new observational study of 841,000 U.S. breast‑cancer patients found that GLP‑1 drugs such as semaglutide and tirzepatide were linked to markedly lower mortality and recurrence rates in women with obesity or type 2 diabetes. In obese survivors, GLP‑1 use cut...
First Participant Dosed in Jade’s Phase II JUNIPER Trial for IgAN
Jade Biosciences has dosed the first participant in its Phase II JUNIPER trial evaluating JADE101 for immunoglobulin A nephropathy (IgAN). The open‑label study will enroll 30 patients and assess safety, tolerability, and early efficacy signals such as protein‑to‑creatinine ratio, eGFR and haematuria...
TOBY Secures US FDA Breakthrough Device Designation for Urine-Based Alzheimer’s Disease Test
The U.S. Food and Drug Administration has granted Breakthrough Device Designation to TOBY’s urine‑based test for Alzheimer’s disease, targeting adults aged 50 and older with cognitive impairment. The test analyzes volatile organic compound patterns in urine using mass spectrometry and...
Sobi Highlights P-III (CORE & CORE2) Trials Results of Olezarsen for Severe Hypertriglyceridemia (sHTG) at EAS 2026
Sobi presented pooled Phase III data from its CORE and CORE2 trials, evaluating the antisense drug olezarsen (Tryngolza) in 455 patients with severe hypertriglyceridemia (TG ≥ 500 mg/dL). At six months, the 80 mg dose cut triglycerides by 66% and the 50 mg dose by 59%...
Scientists Create Supercharged Vitamin K that Helps the Brain Heal Itself
Researchers at Japan's Shibaura Institute of Technology have engineered a novel vitamin K analogue that boosts neuronal differentiation threefold compared with natural MK‑4. By hybridizing vitamin K with retinoic‑acid motifs and a methyl‑ester side chain, the compound—dubbed Novel VK—demonstrates stronger...
One-Time Gene Editing Cuts LDL Cholesterol in Early Hypercholesterolemia Trial
A single intravenous infusion of VERVE‑102, an in‑vivo base‑editing therapy targeting the PCSK9 gene, produced dose‑dependent reductions in PCSK9 protein and LDL cholesterol in a phase 1 trial of 35 adults with heterozygous familial hypercholesterolemia or premature coronary disease. At the...
Retatrutide Reshapes Metabolism in Obesity and Type 2 Diabetes, Study Finds
A post‑hoc analysis of two phase‑2 trials shows that the triple‑receptor agonist retatrutide reshapes fatty‑acid oxidation and insulin‑resistance biomarkers in participants with obesity, with or without type 2 diabetes. Higher doses raised 3‑hydroxybutyrate by up to 198% and altered acyl‑carnitine ratios,...
Recce Pharmaceuticals Signs Distribution Agreement for R327 Diabetic Foot Gel Across MENA
Recce Pharmaceuticals has inked a 10‑year licensing deal with a leading Middle Eastern partner to sell its R327 topical gel for diabetic foot infections across the MENA region, including Saudi Arabia, Egypt, Algeria, Morocco and the GCC. The agreement provides...
Mediwound Ltd (MDWD) Q1 2026 Earnings Call Transcript
MedWound reported Q1 2026 revenue of $1.9 million, a sharp decline from $5.8 million a year earlier, driven primarily by a U.S. government shutdown that delayed contract awards. R&D spending jumped to $4.5 million as the company advanced the Phase III VALUE trial for...
FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
The FDA warned that unapproved compounded versions of GLP‑1 receptor agonists such as semaglutide and tirzepatide are being marketed for weight loss, posing safety and quality risks. Compounded products are not reviewed for efficacy, may be stored improperly, and have...
Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
Kailera Therapeutics reported Q1 2026 results, highlighting major clinical progress across its obesity pipeline and a successful $718.8 million IPO. The company launched a global Phase 3 KaiNETIC program for ribupatide injection, reported strong Phase 2 oral ribupatide weight‑loss data, and disclosed positive...
Niowave, Fresh From Novartis Deal, Starts Building $75M Radioisotope Plant
Niowave announced the construction of a new $75 million actinium‑225 production facility in Lansing, Michigan, slated to begin operations in 2028. The plant will house proprietary superconducting linear accelerators and create about 70 high‑skill jobs in research, engineering, and quality assurance....
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript
Corbus Pharmaceuticals announced that it will present Phase 1/2 data for its oncology candidate CRB‑701 at the upcoming American Society of Clinical Oncology (ASCO) meeting. The data snapshot reflects an April 1 cut, and the company briefed investors via a conference call...
Adcendo Inks MSD Supply Deal to Run ADC-Keytruda Combination Study
Adcendo, a Copenhagen‑based biotech, has signed a supply agreement with MSD for Keytruda to launch a Phase Ib trial of its tissue‑factor‑directed ADC ADCE‑T02 in combination with the checkpoint inhibitor. The study, slated for the second half of the year, will...
FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria; Janssen Seeks a Preliminary Injunction to Block Their Launch
The FDA approved Accord BioPharma’s IMMGOLIS™ and IMMGOLIS INTRI™ as the first interchangeable biosimilars to Janssen’s Simponi® and Simponi ARIA® on May 15, 2026. Both products treat moderately to severely active rheumatoid arthritis, and IMMGOLIS also covers ulcerative colitis. Accord will commercialize the drugs...
New Drug Works Against Diseases Like Measles and Croup
Researchers at Georgia State University have identified GHP-88310, a new oral antiviral candidate that targets orthoparamyxoviruses such as measles and human parainfluenza virus type 3. The drug demonstrated potent, once‑daily efficacy and high tolerability in both rodent and non‑rodent animal models,...
Banner Health Report Shows Arizona Research Driving National Medical Innovation
Banner Health’s $80.5 million research enterprise reported 1,300 active clinical and translational studies in 2025, delivering an FDA‑approved device for severe mitral annular calcification and launching a $74.5 million NIH‑funded Alzheimer prevention trial in Colombia. The organization enrolled more than 89,000 participants...
Lilly Gets Back Into the Vaccine Business With New Deals
Eli Lilly & Co. announced it will acquire three clinical‑stage vaccine developers for up to $3.8 billion, marking a major re‑entry into the infectious‑disease space. The deals are financed largely by cash generated from its blockbuster obesity drugs, such as Mounjaro and...
Brazil Clears First Generic Copy of Novo Nordisk’s Ozempic Shot
Brazil’s health regulator Anvisa approved EMS’s generic semaglutide injection, Ozivy, marking the country’s first GLP‑1 copy of Novo Nordisk’s Ozempic. EMS plans to price Ozivy about 30% lower than the branded shot and expects to launch within 30 days, offering...
Beta Bionics to Launch Its First Insulin Patch Pump to Compete with Insulet
Beta Bionics announced it will debut its first insulin patch pump, called Mint, by the end of Q2 2027 pending FDA clearance. The three‑day wearable features a 200‑unit reservoir and blends reusable and disposable components, linking to the company’s adaptive dosing...
STAT+: Pharmalittle: We’re Reading About a Lilly Gene Therapy for Cholesterol, Three New Lilly Deals, and More
Eli Lilly announced that its gene‑editing therapy, acquired from Verve Therapeutics for $1 billion, lowered LDL cholesterol by 62% in a Phase 1 trial. The study reported no treatment‑related serious adverse events, paving the way for a Phase 2 trial. In parallel, Lilly...
Can a Chaotic FDA Still Deliver on Faster Drug Development?
Recent leadership upheaval at the FDA, including the departure of Commissioner Martin Makary, has sparked concerns about the agency’s ability to maintain momentum on accelerating early‑stage clinical trials in the United States. Nonetheless, industry insiders like Parexel’s Tala Fakhouri argue...
Strep A Vaccine Gets $140mn Backing
Global health philanthropists have launched a $140 million fund, led by Coefficient Giving and donors such as Dustin Moskovitz, to accelerate development of a Group A Streptococcus (Strep A) vaccine. The fund aims to double the pipeline of vaccine candidates and bring at...
Merz Therapeutics and Kvvit Partner to Advance Inbrija in Mainland China, Hong Kong and Macao
Merz Therapeutics has licensed its inhaled levodopa product Inbrija to Chinese biotech Kvvit for exclusive commercialization in mainland China, Hong Kong and Macao. The agreement assigns Merz responsibility for drug supply, global quality oversight and holding the overseas registration certificate,...
STAT+: Eli Lilly to Buy Three Small Vaccine Developers
Eli Lilly announced it will acquire three early‑ and mid‑stage vaccine developers—Curevo, LimmaTech Biologics and Vaccine Company—for a combined price of nearly $4 billion. The deals expand Lilly’s pipeline into vaccines targeting pathogens that cause long‑term health complications. Funding comes from the...
Arthrosi Drug Trial in Gout Delivers for New Owner Sobi
Swedish biotech Sobi’s $1.5 billion acquisition of Arthrosi is yielding results as its gout drug pozdeutinurad met primary goals in the phase 3 REDUCE‑2 trial. The URAT1 inhibitor lowered serum uric acid to ≤6 mg/dl in 69.2% of patients at a 75 mg dose...
Nanoscale Drug Delivery Systems for Ovarian Cancer: Targeting Strategies, Theranostic Platforms, and Translational Challenges
A new review maps the evolution of nanoscale drug delivery systems (DDS) for ovarian cancer, shifting focus from blunt chemotherapy to precision nanomedicine. It outlines three core design strategies—active targeting, microenvironment‑responsive release, and theranostic integration—across carriers such as liposomes, polymeric...
A Photothermally Triggered Cascade Nanodelivery Platform for On‐Demand Nitric Oxide Release in Targeted Hepatocellular Carcinoma Therapy
Researchers have engineered a gold nanocage‑based nanoplatform (GIL9R) that co‑encapsulates indocyanine green and L‑arginine and is surface‑functionalized with the HCC‑targeting peptide 9R‑P201. Upon near‑infrared irradiation, the platform produces localized heat, reactive oxygen species, and catalyzes nitric‑oxide release, delivering combined photothermal,...
Will Lab-Grown Sperm Let Infertile Men Have Children of Their Own?
A US start‑up, Paterna Biosciences, says it can turn testicular stem cells into sperm in the lab, potentially offering a solution for men whose infertility cannot be treated with existing methods. The company claims the technique could enable almost all...
Northern Irish Health Tech Expands in the US After FDA Win
Neurovalens, a Belfast‑based health‑tech startup, received FDA De Novo clearance for its Modius Spero wearable that treats PTSD with low‑level electrical stimulation. The company will begin prescribing the device to U.S. veterans through the Department of Veterans Affairs in July, marking...
Pierre Fabre’s Braftovi Gains CHMP Positive Opinion for mCRC
The European Medicines Agency’s CHMP issued a positive opinion on Pierre Fabre’s Braftovi (encorafenib) combined with cetuximab and Folfox as a first‑line treatment for metastatic colorectal cancer (mCRC) harboring BRAFV600E mutations. The Phase III BREAKWATER trial demonstrated a 51% reduction in...
Pierre Fabre’s Braftovi Gains CHMP Positive Opinion for mCRC
The European Medicines Agency’s CHMP issued a positive opinion for Pierre Fabre’s Braftovi (encorafenib) combined with cetuximab and Folfox as a first‑line treatment of BRAFV600E‑mutant metastatic colorectal cancer. The Phase III BREAKWATER trial showed a 51 % reduction in death risk, extending median...
The European CDMO Model, Powering Biologics Innovation
European contract development and manufacturing organisations (CDMOs) are becoming pivotal as biologics grow in complexity, and 3PBIOVIAN exemplifies this shift with a pan‑European, end‑to‑end model. The company operates GMP‑certified facilities in Pamplona, Spain, and Turku, Finland, offering microbial, mammalian, viral...
Does Ceramide Lipid Metabolism Affect Response to Prostate Cancer Drugs?
Researchers discovered that ceramide lipid metabolism varies by genetic ancestry and influences response to androgen‑receptor pathway inhibitors in metastatic castration‑resistant prostate cancer. Black patients entered treatment with lower total ceramides but higher C24‑to‑C16 ratios, a pattern that flipped during therapy....
AstraZeneca Receives the CHMP Positive Opinion for Camizestrant to Treat Advanced Breast Cancer
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on AstraZeneca’s oral selective estrogen receptor degrader camizestrant, to be used with a CDK4/6 inhibitor for ER‑positive, HER2‑negative advanced breast cancer harboring ESR1 mutations....
Amgen Drug Reviewed Amid Deaths
Amgen’s rare‑disease drug Tavneos (avacopan) resumed sales in Japan after a new warning label was added following 20 reported deaths linked to liver injury. The drug, acquired when Amgen bought ChemoCentryx in 2022, generated $459 million in 2025 sales. In the...
Follow the Money: AI Drug Design Engine, Treating Multiple Myeloma, Quantum Healthcare Platform
Isomorphic Labs closed a $2.1 billion Series B to scale its AI drug‑design engine, while CellCentric secured $220 million to push its oral myeloma candidate, inobrodib, into Phase 3 trials. NVision raised $55 million Series B to merge quantum computing with its POLARIS MRI platform, aiming...
REGENXBIO, Novartis, Dyne Near FDA Submissions in Muscular Dystrophies
A wave of near‑term regulatory activity is reshaping the muscular dystrophy landscape. REGENXBIO reported mixed Phase 3 data for its gene therapy RGX‑202, achieving 93% microdystrophin expression but raising safety flags, while targeting a 2027 launch. Novartis’ $12 billion acquisition of Avidity...
Can Fast, Nimble Clinical Trials Deliver a Drug to Halt the New Ebola Outbreak?
The World Health Organization and African health agencies have launched an adaptive, randomized clinical trial in the Democratic Republic of the Congo to evaluate two therapies—remdesivir and the experimental antibody cocktail MBP134—against the Bundibugyo strain of Ebola. The protocol draws...
Noxopharm Studies Confirm Cancer-Fighting Potential of Sofra Platform
Australian biotech Noxopharm announced new data on its Sofra platform, a TLR8‑activating oligonucleotide technology that could enhance cancer immunotherapy. Preclinical studies demonstrated up to a 200‑fold boost in TLR8 activity in human skin biopsies and nearly three‑fold activation in animal...
NeuroScientific Hails 80% Clinical Response in Crohn’s Stem Cell Program
NeuroScientific Biopharmaceuticals reported that four of five patients with fistulising Crohn’s disease showed a clinical response to its StemSmart mesenchymal stem cell therapy, an 80% response rate. All participants experienced symptom improvement and no serious adverse events were recorded. The...
New Maternal RSV Vaccine Lowers Infant Hospitalization Rates, but Accessibility May Be Limited, Study Finds
A new maternal RSV vaccine introduced in fall 2023 reduces infant hospitalizations, with the Dallas study showing zero hospitalizations among vaccinated infants versus 3% among unvaccinated. Vaccination rates varied sharply by insurance type and race, with private‑insured mothers at 37%...
Response to Comments on "Aluminium Adjuvants in Vaccines and Potential Health Effects: Systematic Review"
The authors of a BMJ systematic review on aluminium adjuvants in vaccines rebut criticisms by highlighting methodological flaws in cited studies and reaffirming that no causal association has been identified. They note that the Joura 2015 HPV vaccine trial cannot...
Roswell Park Scientists Present Five Key Cancer Studies at Clinical Meeting
Roswell Park Comprehensive Cancer Center will showcase five of its own studies at the ASCO 2026 Annual Meeting in Chicago, alongside additional research presented by its faculty and fellows. Highlights include a real‑world analysis of GLP‑1 receptor agonists on hormone‑receptor‑positive breast cancer,...
AstraZeneca, Daiichi Drug Approved as New First-Line Therapy for Tough Type of Breast Cancer
The FDA granted accelerated approval to Datroway (DS‑1062), an antibody‑drug conjugate co‑developed by Daiichi Sankyo and AstraZeneca, as a first‑line therapy for metastatic triple‑negative breast cancer (TNBC). Phase 3 data showed Datroway reduced the risk of disease progression or death by 43%...
ATP2B4 Boosts Chromatin Compaction, Worsens Pancreatic Cancer Radiotherapy Resistance
Researchers have identified the calcium pump ATP2B4 as a driver of chromatin compaction that shields pancreatic tumor DNA from radiation damage. Elevated ATP2B4 levels were detected in roughly two‑thirds of pancreatic ductal adenocarcinoma samples, correlating with poorer radiotherapy outcomes. Genetic...
Discovery of Novel 11 Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor by Machine Learning Enabled Large-Scale Virtual Screening
Researchers applied a machine‑learning‑driven virtual screening workflow to the Mcule catalog of roughly 139.6 million compounds, ultimately identifying a single top candidate, MCULE‑6869845113, as a potent 11beta‑HSD1 inhibitor. The Gradient Boosting Classifier achieved an AUC of 0.88 and Matthews Correlation Coefficient...
Thioflavin-T Derivatives: Novel One- & Two-Photon Amyloid Markers
Researchers have unveiled a new class of thioflavin‑T derivatives that function as both one‑photon and two‑photon fluorescent markers for amyloid aggregates. The compounds exhibit markedly higher quantum yields, expanded two‑photon cross‑sections, and superior photostability compared with the classic Thioflavin‑T dye....
Four Decades of Glioblastoma Targeted Therapy: A Bibliometric and Pharmacological Perspective on Translational Failure and Future Directions
Over the past four decades, more than 5,000 studies have examined targeted therapies for glioblastoma (GBM), yet clinical success remains elusive. The United States and China dominate the research output, with the field progressing through four phases: molecular discovery, first‑generation...